Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934736 · ClinicalTrials.gov registry record · Phase 1
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
A Phase 1 study, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT03934736 is a Phase 1 study that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 119 participants.
The verdict
NCT03934736, a Phase 1 study, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
This is an open-label, single arm study design to evaluate HEPLISAV-B® in adults with ESRD who are initiating or undergoing hemodialysis.
Interventions
- DRUG HEPLISAV-B®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2019-04-22 |
| Est. Completion | 2021-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03934736
The ClinicalTrials.gov registry entry for NCT03934736 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HEPLISAV-B® is the first listed.
NCT03934736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03934736 about?
NCT03934736 is a clinical study titled "HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis". This is an open-label, single arm study design to evaluate HEPLISAV-B® in adults with ESRD who are initiating or undergoing hemodialysis.
What is the current status of trial NCT03934736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2019-04-22. Estimated completion is 2021-09-15.
What interventions are being tested in trial NCT03934736?
The interventions under investigation include: HEPLISAV-B® (DRUG).
Who is sponsoring clinical trial NCT03934736?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.